Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
Therapy Name | GTB-3550 TriKE |
Synonyms | |
Therapy Description |
GTB-3550 TriKE is a tri-specific killer engager molecule that binds to CD16 and CD33 and contains an IL-15 crosslinker, which potentially enhances proliferation of NK-cells, induces cytotoxicity against CD33-expressing tumor cells, and reduces tumor burden (PMID: 26847056). |
Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
---|---|---|---|---|
GTB-3550 TriKE | CD16/IL-15/CD33 TriKE|161533 TriKE|GTB3550 | CD33 Antibody 13 | GTB-3550 TriKE is a tri-specific killer engager molecule that binds to CD16 and CD33 and contains an IL-15 crosslinker, which potentially enhances proliferation of NK-cells, induces cytotoxicity against CD33-expressing tumor cells, and reduces tumor burden (PMID: 26847056). |
Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
---|
Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
---|---|---|---|---|---|---|
NCT03214666 | Phase Ib/II | GTB-3550 TriKE | GTB-3550 Tri-Specific Killer Engager (TriKE®) for High Risk Hematological Malignancies | Terminated | USA | 0 |